Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma
British Journal of Haematology · 2026-01 · 208 (1) · 159-169
DOI: 10.1111/bjh.70219 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 23.10.2025. Verfasst von Takafumi Shichijo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan. Hauptthemen laut MEDLINE: Leukemia-Lymphoma, Adult T-Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI, the SGH Foundation, the Takeda Science Foundation.
Abstract (Originalsprache)
The prognosis for patients with relapsed/refractory (R/R) adult T‐cell leukaemia‐lymphoma (ATL) remains dismal. Recently, valemetostat, a dual inhibitor for enhancer of zeste homologue (EZH) 1 and 2, was approved in Japan for R/R aggressive ATL. However, there is no real‐world data on the efficacy and prognosis of valemetostat. We therefore analysed clinical outcomes in 28 patients with R/R aggressive ATL who received valemetostat at three hospitals in Kumamoto Prefecture between February 2023 and January 2025. The overall response rate (ORR) and complete response (CR) rate were 54.2% and 33.3% respectively. With a median follow‐up of 19.2 months (7.3–21.7) for surviving patients, the median survival time was 15.8 months and median progression‐free survival (PFS) was 8.3 months. The probabilities of 1‐year overall survival (OS) and PFS were 55.8% and 44.1% respectively. Furthermore, the probabilities of 1‐year duration of response and duration of CR were 56.2% and 71.4% respectively. Notably, the probability of 1‐year OS was 90.9% in patients who achieved CR/partial response (PR) (‘responders’) compared to 17.0% in patients who did not achieve CR/PR ( p < 0.001). Thus, valemetostat has the potential to be a reliable therapy for patients with R/R aggressive ATL, especially for responders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
- Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
- Department of Hematology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
ORCID-Profile: Takafumi Shichijo, Hiro Tatetsu, Kisato Nosaka, Jun-Ichirou Yasunaga
Förderung
- JSPS KAKENHI
- the SGH Foundation
- the Takeda Science Foundation
Zitieren
APA
Shichijo, T., Tatetsu, H., Higuchi, Y., Miyakawa, T., Nosaka, K., Nakamura, T., Endo, S., Yamada, A., Wada, A., Okamoto, Y., Kawakita, T., Suzushima, H., Matsuoka, M., & Yasunaga, J. I. (2026). Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma. British Journal of Haematology, 208(1), 159-169. https://doi.org/10.1111/bjh.70219
Vancouver
Shichijo T, Tatetsu H, Higuchi Y, Miyakawa T, Nosaka K, Nakamura T, et al. Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma. British Journal of Haematology. 2026;208(1):159-169. doi:10.1111/bjh.70219
BibTeX
@article{Shichijo2026,
author = {Shichijo, Takafumi and Tatetsu, Hiro and Higuchi, Yusuke and Miyakawa, Toshikazu and Nosaka, Kisato and Nakamura, Takahisa and Endo, Shinya and Yamada, Asami and Wada, Atsushi and Okamoto, Yuki and Kawakita, Toshiro and Suzushima, Hitoshi and Matsuoka, Masao and Yasunaga, Jun-Ichirou},
title = {Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {1},
pages = {159--169},
doi = {10.1111/bjh.70219}
}
EUVIMED